Federal Institute for Drugs and Medical Devices
BfArM is Germany's federal regulatory authority for pharmaceuticals and medical devices, headquartered in Bonn with approximately 1,300 employees. It operates statutory drug and device approval, pharmacovigilance, and national healthcare databases, funded by the Federal Ministry of Health budget.
- Company typePrivate
- Founded1994
- HeadquartersBonn, Germany
- Headcount1,001–5,000
- GTM typeB2B
- OfferingServices
What Federal Institute for Drugs and Medical Devices does
The Federal Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte, BfArM) is an independent German federal higher authority within the portfolio of the Federal Ministry of Health (BMG), established in 1994 from the former Federal Health Office. Headquartered in Bonn with an additional office in Berlin, BfArM employs approximately 1,300 staff and is responsible for the centralized approval, pharmacovigilance, and post-market surveillance of pharmaceuticals and medical devices in Germany. It is described as the largest drug approval authority in Europe, with experts contributing to EMA scientific committees including CHMP and PRAC, and operates the Bundesopiumstelle (Federal Opium Agency) division for controlled substances and medical cannabis regulation.
BfArM's core technology platform consists of regulatory information systems that anchor its statutory mandate. These include DMIDS for medical device registration and clinical investigations, AMIce for drug product information, the German Clinical Trials Register (DRKS), the DiGA/DiPA Directory for digital health applications, the Organ and Sperm Donor Registers, the OID Registry for German healthcare identifiers, and a Terminology Server providing ICD, OPS, ATC, SNOMED CT, and LOINC classification systems. DACO functions as Germany's national contact point for the European Health Data Space. The technology stack is built around integration and interoperability with EU regulatory networks, including EUDAMED and the EMA's Clinical Trials Information System (CTIS).
BfArM does not generate commercial revenue. It is funded through annual federal budget allocations from the BMG, and its core regulatory services are provided free of charge to pharmaceutical companies, medical device manufacturers, healthcare providers, and citizens. Limited administrative fees may apply for specific applications. The go-to-market model is institutional rather than commercial: BfArM operates through official regulatory application portals, public databases, EU regulatory network participation, and stakeholder engagement via newsletters, publications, and educational events. Its customer base is defined by statutory mandate — every pharmaceutical and medical device company operating in Germany interacts with BfArM for approval and ongoing compliance.
Federal Institute for Drugs and Medical Devices firmographics
Firmographics- Name
- Federal Institute for Drugs and Medical Devices
- Legal name
- Bundesinstitut für Arzneimittel und Medizinprodukte
- Website
- https://bfarm.de
- Company type
- Private
- Founded year
- 1994
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Short description
- BfArM is Germany's federal regulatory authority for pharmaceuticals and medical devices, headquartered in Bonn with approximately 1,300 employees. It operates statutory drug and device approval, pharmacovigilance, and national healthcare databases, funded by the Federal Ministry of Health budget.
- Ownership category
- akta.pro rank
Federal Institute for Drugs and Medical Devices industry classification
Industry- Product category
- Pharmaceutical and Medical Device Regulatory Services
- akta.pro industry
- Drug Regulators (Human Pharmaceuticals)Healthcare & Life Sciences/Public Health, Government & Regulators/Medicines & Healthcare Product Regulators (Drugs/Biologics/Devices)Clinical Trials Authorization & Oversight (GCP)Healthcare & Life Sciences/Public Health, Government & Regulators/Medicines & Healthcare Product Regulators (Drugs/Biologics/Devices)Controlled Substances & Pharmacy Regulation AuthoritiesHealthcare & Life Sciences/Public Health, Government & Regulators/Health Policy, Regulation & Compliance AuthoritiesPharmacovigilance, Medication Safety & Controlled Substance Diversion Monitoring
Keywords
Where Federal Institute for Drugs and Medical Devices is headquartered
LocationHeadquarters
- HQ city
- Bonn
- HQ country
- Germany
- HQ region
- Europe
Offices2 records
Markets served
Federal Institute for Drugs and Medical Devices business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Infrastructure
Revenue model
- Federal Government Budget: Funded by the German Federal Ministry of Health (BMG) through annual federal budget allocations. Revenue comes from taxpayer funds allocated for regulatory and public health functions.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Other | Regulatory Services - No direct charges to public |
Go-to-market motion1 record
Distribution channels3 records
Marketing channels7 records
Federal Institute for Drugs and Medical Devices product offering
Product offeringCore offering
BfArM provides regulatory oversight for pharmaceuticals and medical devices in Germany, including drug market authorization, clinical trial approvals, pharmacovigilance and adverse event reporting, medical device registration and conformity assessment under MDR/IVDR, and post-market surveillance. It also operates national information systems and registries covering medicinal products, medical devices, clinical trials, organ and sperm donation, healthcare terminologies, and the European Health Data Space. These services support pharmaceutical companies, medical device manufacturers, healthcare providers, and citizens within Germany's statutory regulatory framework.
Product overview
The Federal Institute for Drugs and Medical Devices (BfArM) is Germany's federal regulatory agency responsible for drug approvals, medical device oversight, and healthcare data management. The organization operates multiple information systems and registries as part of its regulatory mandate: DMIDS handles medical device documentation and notifications; AMIce provides drug product information; the Terminologieserver delivers access to healthcare coding systems (ICD, OPS, SNOMED CT, LOINC); DiGA/DiPA Directory catalogs approved digital health applications; DACO coordinates European Health Data Space implementation; and various national registries manage organ donation, sperm donation, and clinical trial registration. These systems serve regulatory compliance, public health transparency, and healthcare interoperability functions rather than commercial product offerings.
Differentiator
Problem solved
Functional benefit
Brands
- Bundesopiumstelle (Federal Opium Agency): Division responsible for narcotics regulation, controlled substances, medical cannabis, precursors, T-prescriptions, and substitution register
Products and services
- DMIDS (Medical Devices Information and Documentation System)
Quantifiable outcome
- Centralized drug approval and safety monitoring for Germany
- +2 more outcomes
Companies that use Federal Institute for Drugs and Medical Devices
Customer profileNamed customers5 records
Segments4 records
Ideal customer profiles4 records
Federal Institute for Drugs and Medical Devices technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature9 records
Federal Institute for Drugs and Medical Devices partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered core and major.
- European Medicines Agency (EMA)coreBfArM experts actively contribute to EMA scientific committees including CHMP (Committee for Medicinal Products for Human Use) and PRAC (Pharmacovigilance Risk Assessment Committee). As the largest drug approval authority in Europe, BfArM plays a central role in EU pharmaceutical regulation.
- World Health Organization (WHO)coreBfArM operates as a WHO Collaborating Centre and participates in international regulatory harmonization through ICH (International Council for Harmonisation). Also involved in GHPP (Global Health Protection Programme) for international capacity building.
- EU4Health ProgrammemajorParticipation in EU4Health programme for public health cooperation, including HDP4Germany project for health data utilization in the European Health Data Space.
- OrphanetmajorBfArM coordinates Orphanet Germany, providing information on rare diseases and orphan drugs. Part of international Orphanet network for rare disease documentation.
- European Health Data Space (EHDS)coreBfArM operates DACO (Data Access and Coordination Office) as the national contact point for the European Health Data Space, enabling cross-border health data utilization and establishing the Cross-Border Gateway.
- German Federal Ministry of Health (BMG)coreBfArM operates as a federal upper authority under the BMG, implementing health policies and regulatory frameworks including the Medical Research Act (MFG) in cooperation with PEI.
- Paul-Ehrlich-Institut (PEI)coreBfArM works closely with PEI (Germany's Federal Institute for Vaccines and Biomedical Medicines) on implementation of the Medical Research Act (Medizinforschungsgesetz) and joint regulatory initiatives.
- Federal States (Bundesländer)majorCollaboration with German federal states for implementation of drug and medical device regulations, including state-level enforcement authorities for market surveillance and pharmacy oversight.
Scale indicators3 records
Recent moves6 records
Expansion highlights5 records
Federal Institute for Drugs and Medical Devices competitors and assessment
Company assessmentDirect peers
- Agenzia Italiana del Farmaco (AIFA): Italy's national pharmaceutical authority, comparable to BfArM in covering drug approvals, pharmacovigilance, and pricing/reimbursement functions within the EU regulatory framework.
- Agence nationale de sécurité du médicament (ANSM): France's national medicines agency with a mandate closely parallel to BfArM covering drug approvals, pharmacovigilance, medical device oversight, and controlled substances, making it a strong European national peer.
- European Medicines Agency (EMA): The EU-level pharmaceutical regulator that coordinates with BfArM. BfArM experts contribute to EMA scientific committees (CHMP, PRAC), making EMA the closest institutional peer operating at the supranational level.
- Swissmedic: Switzerland's national regulatory authority for therapeutic products, with a similar scope covering pharmaceuticals, medical devices, and clinical trial oversight. Comparable in being a non-EU European national authority.
- Medicines and Healthcare products Regulatory Agency (MHRA): The UK's national regulator for medicines and medical devices, post-Brexit an independent authority similar in scope to BfArM. Comparable in mandate covering drug approvals, devices, pharmacovigilance, and clinical trial oversight.
- Paul-Ehrlich-Institut (PEI): Germany's federal institute for vaccines and biomedicines, a sister agency to BfArM. PEI and BfArM jointly implement the Medical Research Act and cover complementary regulatory domains, making it the most direct national peer.
Broad incumbents
- Health Canada - Health Products and Food Branch: The Canadian federal regulator for drugs and medical devices, comparable in scope to BfArM with additional food oversight. Like BfArM, it operates as a national authority coordinating with international peers.
- Pharmaceuticals and Medical Devices Agency (PMDA): Japan's regulatory agency for pharmaceuticals and medical devices, comparable in mandate (drug/device reviews, pharmacovigilance, clinical trials) and in operating as a national authority in a large healthcare market.
- Therapeutic Goods Administration (TGA): Australia's regulatory authority for therapeutic goods including medicines and medical devices. Comparable in covering the full spectrum of pharmaceutical and device regulation at the national level.
- U.S. Food and Drug Administration (FDA): The largest national drug and medical device regulator globally. While operating under a different legal framework, FDA's combination of drug approvals, device oversight, pharmacovigilance, and digital health regulation makes it the global benchmark peer.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
Federal Institute for Drugs and Medical Devices social profiles
Digital presenceFederal Institute for Drugs and Medical Devices financial estimates
Financial estimateRevenue estimate
Valuation estimate
Federal Institute for Drugs and Medical Devices leadership team
Management profileNumber of profiles
Profiles1 record
Federal Institute for Drugs and Medical Devices subsidiaries and ownership
Company hierarchySubsidiaries1 record
Federal Institute for Drugs and Medical Devices funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Federal Institute for Drugs and Medical Devices M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Federal Institute for Drugs and Medical Devices
What does Federal Institute for Drugs and Medical Devices do?
BfArM provides regulatory oversight for pharmaceuticals and medical devices in Germany, including drug market authorization, clinical trial approvals, pharmacovigilance and adverse event reporting, medical device registration and conformity assessment under MDR/IVDR, and post-market surveillance. It also operates national information systems and registries covering medicinal products, medical devices, clinical trials, organ and sperm donation, healthcare terminologies, and the European Health Data Space. These services support pharmaceutical companies, medical device manufacturers, healthcare providers, and citizens within Germany's statutory regulatory framework.
Is Federal Institute for Drugs and Medical Devices a public or private company?
Federal Institute for Drugs and Medical Devices is a private company. It is classified as state government owned and is currently operating.
When was Federal Institute for Drugs and Medical Devices founded?
Federal Institute for Drugs and Medical Devices was founded in 1994. It employs 1,001 to 5,000 people.
Where is Federal Institute for Drugs and Medical Devices based?
Federal Institute for Drugs and Medical Devices is headquartered in Bonn, Germany, in the Europe region.
How does Federal Institute for Drugs and Medical Devices make money?
One revenue line is on record: federal Government Budget.
Who are Federal Institute for Drugs and Medical Devices's main competitors?
Direct peers on record are Agenzia Italiana del Farmaco (AIFA), Agence nationale de sécurité du médicament (ANSM), European Medicines Agency (EMA), Swissmedic, Medicines and Healthcare products Regulatory Agency (MHRA) and Paul-Ehrlich-Institut (PEI). Broad incumbents are Health Canada - Health Products and Food Branch, Pharmaceuticals and Medical Devices Agency (PMDA), Therapeutic Goods Administration (TGA) and U.S. Food and Drug Administration (FDA).
Does Federal Institute for Drugs and Medical Devices have an API?
No public API is recorded for Federal Institute for Drugs and Medical Devices.
What industry is Federal Institute for Drugs and Medical Devices in?
Federal Institute for Drugs and Medical Devices's product category is Pharmaceutical and Medical Device Regulatory Services. Its primary akta.pro industry code is HLAJADAA, Drug Regulators (Human Pharmaceuticals), with a secondary code of HLAJADAF, Clinical Trials Authorization & Oversight (GCP).